[ARWR] Arrowhead Pharmaceuticals, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 1.59 Change: 0.22 (16.06%)
Ext. hours: 1.59 Change: 0 (0%)

chart ARWR

Refresh chart

Strongest Trends Summary For ARWR

ARWR is in the medium-term up 133% in 1 year. In the long-term up 1727% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Arrowhead Research Corporation develops novel drugs to treat intractable diseases in the United States. The company?s principal product candidates comprise ARC-520, an RNAi-based therapeutic that is in Phase IIa clinical trial to treat chronic hepatitis B virus infection; and ARC-AAT, a novel unlocked nucleobase analog containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. Its platform technology include Dynamic Polyconjugate platform, an RNAi delivery system that addresses multiple organ systems and cell types. The company is also involved in the development of Adipotide, which is in phase I clinical trial for the treatment of obesity and metabolic disorders; and CRLX-101 that is in phase II clinical trial to treat various cancer types, including relapsed renal cell carcinoma, relapsed ovarian cancer, and non-metastatic rectal cancer. It has research collaboration and license agreement with Shire AG to develop and commercialize targeted peptide-dr

Fundamental Ratios
Shares Outstanding EPS-0.89 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 0% Sales Growth - Q/Q-74.27% P/E-1.79
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-52.54% ROE-59.17% ROI-56.98%
Current Ratio9.1 Quick Ratio Long Term Debt/Equity0.01 Debt Ratio0.09
Gross Margin Operating Margin-29638.3% Net Profit Margin-28158.4% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities210 K Cash From Investing Activities4.3 M Cash From Operating Activities-40.57 M Gross Profit
Net Profit-28.68 M Operating Profit-29.63 M Total Assets162.38 M Total Current Assets120.15 M
Total Current Liabilities13.21 M Total Debt870 K Total Liabilities17.63 M Total Revenue40 K
Technical Data
High 52 week29.98 Low 52 week10.74 Last close29.05 Last change-0.31%
RSI44.77 Average true range1.24 Beta0.59 Volume4.6 M
Simple moving average 20 days0.31% Simple moving average 50 days5.31% Simple moving average 200 days51.5%
Performance Data
Performance Week-0.24% Performance Month10.5% Performance Quart48.9% Performance Half85.5%
Performance Year80.21% Performance Year-to-date133.9% Volatility daily2.62% Volatility weekly5.86%
Volatility monthly12.01% Volatility yearly41.59% Relative Volume448.74% Average Volume2.07 M
New High New Low


2019-10-04 12:11:00 | Medical stocks on the move: AbbVie, Arrowhead Pharmaceuticals and Zynex

2019-10-02 16:15:00 | Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics

2019-09-30 16:00:00 | Arrowhead Pharmaceuticals to Participate in Upcoming October 2019 Conferences

2019-09-27 09:15:00 | ARWR: Broad-Based Pipeline Progress. Three Pivotal Studies, Value-Inflection Opportunities In View.

2019-09-20 16:00:00 | Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635c4

2019-09-20 10:19:07 | Is Arrowhead Pharmaceuticals, Inc.'s NASDAQ:ARWR CEO Paid Enough Relative To Peers?

2019-09-16 03:00:00 | Arrowhead Pharmaceuticals Presents Initial Top-Line Clinical Data and Preclinical Data on RNAi Candidates ARO-APOC3 and ARO-ANG3

2019-09-09 06:51:10 | Should First Trust Small Cap Growth AlphaDEX Fund FYC Be on Your Investing Radar?

2019-09-08 19:28:39 | Here's Why Arrowhead Pharmaceuticals Rose 17.6% in August

2019-08-30 16:00:00 | Arrowhead Pharmaceuticals to Participate in Upcoming September 2019 Conferences

2019-08-29 16:21:42 | Why This Newly Profitable Biotech Stock Is Flirting With A Breakout

2019-08-29 11:02:00 | Arrowhead Pharmaceuticals and three other stocks to watch

2019-08-28 15:16:47 | Is Arrowhead Pharmaceuticals Inc ARWR’s Recently Published U.S. Patent Application A Blockbuster?

2019-08-28 07:30:00 | Arrowhead Collaborator Janssen Begins REEF-1 Phase 2b Combination Study in Patients with Chronic Hepatitis B Infection

2019-08-21 12:37:59 | Arrowhead Pharmaceuticals: Buy at the High?

2019-08-19 11:44:09 | Arrowhead Pharma Shares Quietly See Big Buy Demand

2019-08-15 11:59:07 | Could The Arrowhead Pharmaceuticals, Inc. NASDAQ:ARWR Ownership Structure Tell Us Something Useful?

2019-08-15 09:00:38 | BioBoyScout’s Online Biotech Valuation Calculators Help Small Investors See Value in Arrowhead Pharmaceuticals ARWR

2019-08-08 07:30:00 | Arrowhead Pharmaceuticals Doses First Patient in SEQUOIA Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

2019-08-06 07:17:09 | Edited Transcript of ARWR earnings conference call or presentation 5-Aug-19 8:30pm GMT

2019-08-06 06:00:00 | What You'll Want to Know About Arrowhead Pharmaceuticals' Q3 Update

2019-08-05 23:23:28 | Arrowhead Research Corp ARWR Q3 2019 Earnings Call Transcript

2019-08-05 20:02:44 | How Analysts View Arrowhead Pharmaceuticals

2019-08-05 16:00:00 | Arrowhead Pharmaceuticals Reports Fiscal 2019 Third Quarter Results

2019-07-24 07:30:00 | Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Third Quarter Results

2019-07-16 16:00:00 | Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-ANG3

2019-07-10 07:27:42 | How Does Arrowhead Pharmaceuticals, Inc. NASDAQ:ARWR Affect Your Portfolio Volatility?

2019-07-08 07:30:00 | Arrowhead Pharmaceuticals to Participate in Roth RNA Revolution Conference

2019-06-28 16:31:16 | Highly Rated Biotech Downgraded After Breaking Out And Running 39%

2019-06-28 07:32:52 | The Daily Biotech Pulse: Chiasma To Join R3K Index, EU Rejects Amgen's Osteoporosis Drug Application, Karuna IPO

2019-06-28 06:45:00 | Arrowhead Pharma Heads Down Midday After Downgrade

2019-06-27 07:30:00 | Arrowhead Pharmaceuticals Receives Fast Track Designation for ARO-AAT for Treatment of Alpha-1 Liver Disease

2019-06-24 13:38:49 | Hedge Funds Have Never Been This Bullish On Arrowhead Pharmaceuticals, Inc. ARWR

2019-06-21 18:45:00 | Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635c4

2019-06-21 07:30:00 | Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-APOC3

2019-06-14 14:59:58 | 7 Top-Rated Biotech Stocks to Invest In Today

2019-06-12 15:32:37 | Edited Transcript of ARWR earnings conference call or presentation 12-Dec-17 9:30pm GMT

2019-06-10 10:02:01 | Read This Before Judging Arrowhead Pharmaceuticals, Inc.'s NASDAQ:ARWR ROE

2019-06-10 06:30:00 | Here's Why Arrowhead Pharmaceuticals Surged 31.9% in May

2019-05-31 16:00:00 | Arrowhead Pharmaceuticals to Present at Upcoming June 2019 Conferences

2019-05-21 16:27:00 | Here's Why Arrowhead Pharmaceuticals Skyrocketed 12.7% Today

2019-05-21 07:40:14 | The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails

2019-05-20 17:56:00 | Kontoor Brands and Arrowhead Pharmaceuticals Set to Join S&P SmallCap 600

2019-05-20 15:45:00 | ARWR: ARO-AAT Ph 2/3 Detailed, Could Serve as FDA Pivotal Study. Continued Broad-Based Pipeline Progress

2019-05-09 06:19:33 | Edited Transcript of ARWR earnings conference call or presentation 8-May-19 8:30pm GMT

2019-05-09 01:23:54 | Arrowhead Research Corp ARWR Q2 2019 Earnings Call Transcript

2019-05-08 16:06:29 | Arrowhead Research: Fiscal 2Q Earnings Snapshot

2019-05-08 16:00:00 | Arrowhead Pharmaceuticals Reports Fiscal 2019 Second Quarter Results

2019-05-08 14:30:00 | Arrowhead Pharmaceuticals, Inc. to Host Earnings Call

2019-05-02 16:05:56 | Here’s What Hedge Funds Think About Arrowhead Pharmaceuticals, Inc. ARWR